|
|
|
April 13, 2007
eyeonics’ Sales Increase 36% and Records Profitable Quarter
Crystalens, approved by the FDA in November 2003,
is an intraocular lens which accommodates just like a
natural lens. By using the eye's muscles to move the lens
forward and backwards, patients can focus through a continuous
range of vision including near, far, and everywhere in
between. In the April 13 press release below, eyeonics
announced that revenues for the first quarter ended March
31, 2007 totaled $5.5 million, up 36 percent from revenues
in the same period last year.
--------------------------------
eyeonics™, the developer of the crystalens®,
the first and only FDA approved accommodating intraocular
lens, announced today that revenues for the first quarter
ended March 31, 2007 totaled $5.5 million, up 36 percent
from revenues in the same period last year. At the same
time, implants have grown more than 45 percent year-over-year.
The crystalens has now been implanted in more than 70,000
patients worldwide. The Company also reported that for
the quarter ending March 31, 2007, it recorded an operating
profit of $500,000 compared to a net loss of $2.3 million
in the prior year's first quarter.
Jeffrey Whitman, M.D., Chief of Surgery at Key-Whitman
Eye Center in Dallas, TX and a world leader in crystalens
implantation, said, "The premium IOL market is still
in its early stages and the current and future product
offerings from eyeonics will stimulate future growth of
this market. Over the past 18 months, most ophthalmologists
have tried the competing premium lenses and it is now
becoming clear that accommodating technology is the preferred
technology for a majority of surgeons."
Back to News
|
|
| |
